Literature DB >> 16554332

Learning from the TGN1412 trial.

Michael Goodyear.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 16554332      PMCID： PMC1410845          DOI： 10.1136/bmj.38797.635012.47

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  6 in total

1.  The contract research organization and the commercialization of scientific research.

Authors:  Philip Mirowski; Robert Van Horn
Journal:  Soc Stud Sci       Date:  2005-08       Impact factor: 3.885

Review 2.  Principles for international registration of protocol information and results from human trials of health related interventions: Ottawa statement (part 1).

Authors:  Karmela Krleza-Jerić; An-Wen Chan; Kay Dickersin; Ida Sim; Jeremy Grimshaw; Christian Gluud
Journal:  BMJ       Date:  2005-04-23

3.  Is society losing control of the medical research agenda?

Authors:  Brendan Delaney
Journal:  BMJ       Date:  2006-03-17

4.  CD28 superagonists put a break on autoimmunity by preferentially activating CD4+CD25+ regulatory T cells.

Authors:  Niklas Beyersdorf; Thomas Hanke; Thomas Kerkau; Thomas Hünig
Journal:  Autoimmun Rev       Date:  2005-07-07       Impact factor: 9.754

5.  The murine homologue of the T lymphocyte antigen CD28. Molecular cloning and cell surface expression.

Authors:  J A Gross; T St John; J P Allison
Journal:  J Immunol       Date:  1990-04-15       Impact factor: 5.422

6.  Registering clinical trials.

Authors:  Kay Dickersin; Drummond Rennie
Journal:  JAMA       Date:  2003-07-23       Impact factor: 56.272
  6 in total
  27 in total

Review 1.  Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics.

Authors:  Dhaval K Shah
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-15       Impact factor: 2.745

Review 2.  Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.

Authors:  Craig G Hartford; Kasia S Petchel; Hani Mickail; Susana Perez-Gutthann; Mary McHale; John M Grana; Paula Marquez
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

3.  Further lessons from the TGN1412 tragedy.

Authors:  Michael D E Goodyear
Journal:  BMJ       Date:  2006-08-05

4.  Biological therapies: concepts and challenges.

Authors:  Markus Müller
Journal:  Wien Klin Wochenschr       Date:  2006-09       Impact factor: 1.704

5.  From pharmacology to immunopharmacology.

Authors:  Adam Cohen
Journal:  Br J Clin Pharmacol       Date:  2006-10       Impact factor: 4.335

6.  Immunomodulation strategies for preventing vascular disease of the brain and heart: workshop summary.

Authors:  John Hallenbeck; Gregory Del Zoppo; Tom Jacobs; Antoine Hakim; Stephen Goldman; Ursula Utz; Ahmed Hasan
Journal:  Stroke       Date:  2006-11-02       Impact factor: 7.914

7.  Medicine. Moving toward transparency of clinical trials.

Authors:  Deborah A Zarin; Tony Tse
Journal:  Science       Date:  2008-03-07       Impact factor: 47.728

8.  Should we tolerate tolerability as an objective in early drug development?

Authors:  A Cohen
Journal:  Br J Clin Pharmacol       Date:  2007-09       Impact factor: 4.335

Review 9.  Thinking inside the box. To cope with an increasing disease burden, drug discovery needs biologically relevant and predictive testing systems.

Authors:  Lars E Sundstrom
Journal:  EMBO Rep       Date:  2007-07       Impact factor: 8.807

10.  Comment on 'The ethics of animal research' by Festing & Wilkinson.

Authors:  Kathy Archibald; Margaret Clotworthy
Journal:  EMBO Rep       Date:  2007-09       Impact factor: 8.807
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.